Keyword: Chris Viehbacher
News
25.10.2012
- French drugmaker Sanofi forecast 2012 earnings would fall less than expected as cost cuts and demand for diabetes and rare disease drugs cushion the blow from patent expiries...
News
28.04.2012
- French drugmaker Sanofi posted better-than-expected quarterly results, bolstered by strong emerging markets, breaking with a trend of earnings misses by European rivals AstraZeneca...
News
12.03.2012
- Bayer is sounding out its debt financing options with banks to prepare for takeover opportunities such as one that may arise from Pfizer's mooted exit from veterinary medicine...
News
22.12.2011
- GlaxoSmithKline executive German Pasteris is in charge of an Alzheimer's treatment that is years from reaching the market, if it ever does. But he already wants to make sure the...
News
04.04.2011
- French drugmaker Sanofi-Aventis completed its improved $20.1 billion offer for Genzyme allowing it to begin merging the U.S. biotech into its business and add rare diseases to its...
News
30.03.2011
- Certificates related to Sanofi-Aventis's $20.1 billion acquisition of U.S. biotech firm Genzyme could begin trading on Nasdaq as soon as April 4, depending on the outcome of its...
News
08.03.2011
- Genzyme Chief Executive Henri Termeer is set to walk away with nearly $160 million when the sale of his company to French drugmaker Sanofi-Aventis is final - and stands to earn...
News
14.02.2011
- Genzyme Corp investors' confidence that the U.S. biotech is close to an agreement to be taken over by Sanofi-Aventis could be shaken if the French drugmaker extends its tender...
